Observational studyClinical and experimental medicine2025

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide.

I Rizzello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.